Hematologic parameters pinpointed a group of hospitalized patients who were most likely to benefit from baricitinib.
In the ACTT-2 study, patients hospitalized with COVID-19 who received remdesivir plus the immunomodulator baricitinib recovered sooner than those who received remdesivir alone (NEJM JW Infect Dis Dec 17 2020 and N Engl J Med Mar 4 2021; 384:795) Now, investigators report a post hoc analysis of ACTT-2 to assess whether a risk profile based on hematologic parameters (low absolute lymphocyte count, high absolute neutrophil count, and low platelet count at baseline) identifies a group most likely to benefit from baricitinib. This “ACTT risk profile” was derived from the ACTT-1 study, in which the profile predicted risk for clinical progression among hospitalized patients.
A total of 999 participants from ACTT-2 were included. Among participants …
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)